Evidence map›Paper›PMID 32161221›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Whole-brain Radiation and Pembrolizumab Treatment for a Non-small-cell Lung Cancer Patient with Meningeal Carcinomatosis Lacking Driver Oncogenes Led to a Long-term Survival.

Koki Nakashima, Yoshiki Demura, Masahiro Oi, Mio Tabata, Toshihiko Tada, Kohei Shiozaki, Masaya Akai, Tamotsu Ishizuka

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Koki NakashimaDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan.
Yoshiki DemuraDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan.
Masahiro OiDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan.
Mio TabataDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan.
Toshihiko TadaDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan.
Kohei ShiozakiDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan.
Masaya AkaiDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan.
Tamotsu IshizukaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.
Fukui Red Cross Hospital · JPUniversity of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a 66-year-old woman with advanced lung adenocarcinoma [programmed cell death and its ligand 1 (PD-L1) tumor proportion score 60%] lacking driver oncogenes in whom meningeal carcinomatosis, along with sudden onset dizziness, deafness, and consciousness disturbance, appeared after second-line chemotherapy. Whole-brain radiation therapy (WBRT) and Pembrolizumab were subsequently administered, and third-line chemotherapy with Pembrolizumab is now ongoing. At the time of writing, the patient has achieved a 23-month survival without disease progression. Our findings suggest that the combination of WBRT and an immune checkpoint inhibitor is effective for non-small-cell lung cancer patients lacking driver oncogenes who develop meningeal carcinomatosis.

Indexed as

AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBrain NeoplasmsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMeningeal CarcinomatosisOncogenesTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumabimmune checkpoint inhibitormeningeal carcinomatosisnon-small-cell lung cancerPembrolizumabwhole-brain radiation therapy

Identifiers

PMID32161221
PMCPMC7332633
OpenAlexW3010750816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.